Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Hovione and Solvias Announce a Collaboration

Published: Friday, November 30, 2012
Last Updated: Thursday, November 29, 2012
Bookmark and Share
Collaboration to provide for improved drug solubility.

Hovione and Solvias have announced the establishment of a collaboration focused on the development and GMP supply of pharmaceutical co-crystals.

This strengthens Hovione’s expertise and experience in overcoming drug delivery challenges and also the supply of GMP materials from phase I to commercial scale, with Solvias’ excellence in solid state chemistry.

Hovione offers a series of innovative particle engineering technologies focused on amorphous solid dispersions, crystal design and reduction and control of particle size.

The collaboration provides Hovione access to Solvias’ co-crystallization expertise and capabilities, thus reinforcing and complementing the crystal design solutions to overcome poor bioavailability and other drug delivery challenges.

Solvias continues its strategy of partnering to enhance access to its solid-state solutions.

“We are delighted to announce this collaboration with Solvias increasing the breadth of drug delivery solutions through our Particle Design offering. Solvias has a tremendous reputation for science, quality and expertise in crystal design for improved drug performance. This agreement reinforces our strategy of combining strengths with innovative companies to allow our customers a seamless and integrated approach to their drug delivery challenges.” said Dr. Colin Minchom, Hovione’s Vice President of Particle Design.

Dr. Martina Diekmann, Solvias’ Global Head of Business Development Analytics commented “Solvias is delighted to work with Hovione. In establishing this agreement with Hovione, we are able to generate added value for our customers and to help them solving their drug delivery requirements.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Hovione Acquires a Formulation Plant
Acquisition to further boost development and manufacturing capabilities for inhalation and oral dosage forms.
Saturday, October 24, 2015
Hovione to Expand its New Jersey Facility
Doubling of capacity is expected to be fully operational in early 2017.
Saturday, October 03, 2015
Hovione Installs a New Large Scale Spray Drying Unit
New unit is specifically designed to handle high potency APIs.
Thursday, July 09, 2015
Hovione Announces a Co-promotion and Collaboration Agreement with Ligand
Agreement to provide Hovione’s customers efficient access to Captisol® technology.
Friday, September 06, 2013
Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!